Marksans Pharma Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has delivered good profit growth of 25.0% CAGR over last 5 years
- Company is almost debt free
- Latest quarter profit grew 43.6% YoY, showing strong momentum
- Company has delivered good sales growth of 17.5% CAGR over last 5 years
- Company generates healthy free cash flow
- Company has a consistent dividend-paying track record
CONS
- A large part of profit comes from other income (26.4% of PBT)
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.44x)
- Though reporting repeated profits, the company pays out little dividend (13.6%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1868.50 | 37.06 | 448315.74 | 0.86 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9482.75 | 86.06 | 251737.22 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4931.90 | 86.01 | 187593.62 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1129.00 | 24.95 | 112618.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1368.00 | 32.79 | 110515.04 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1933.25 | 95.54 | 104455.86 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1690.00 | 26.19 | 97238.86 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2092.00 | 17.30 | 95660.02 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1143.20 | 29.61 | 95420.61 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2266.00 | 45.82 | 93596.02 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2439.55 | 38.29 | 68850.12 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| MARKSANS | 330.45 | 28.98 | 14974.80 | 0.27 | 159.41 | 173.89 | 840.80 | 35.61 | 21.10 | 25.34 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 182 | 205 | 241 | 225 | 255 | 309 | 312 | 299 | 320 | 320 | 340 | 362 | 321 | |
| 155 | 167 | 199 | 191 | 213 | 245 | 260 | 248 | 250 | 248 | 264 | 256 | 248 | |
| Operating Profit | 27 | 37 | 42 | 34 | 41 | 63 | 52 | 52 | 70 | 72 | 75 | 106 | 73 |
| OPM % | 14.70% | 18.22% | 17.39% | 15.06% | 16.21% | 20.55% | 16.57% | 17.29% | 21.91% | 22.49% | 22.21% | 29.31% | 22.72% |
| 33 | 16 | 1 | 12 | 8 | 20 | 31 | 7 | 2 | 58 | 16 | 27 | 17 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 5 | 8 | 8 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 9 | 9 | 9 |
| Profit before Tax | 54 | 44 | 35 | 38 | 42 | 76 | 75 | 50 | 64 | 121 | 82 | 124 | 90 |
| Tax % | 18.75% | 29.69% | 26.91% | 14.09% | 24.30% | 17.20% | 25.78% | 24.67% | 24.41% | 17.85% | 25.82% | 26.09% | 23.68% |
| Net Profit | 44 | 31 | 25 | 33 | 32 | 63 | 55 | 38 | 48 | 100 | 61 | 92 | 69 |
| 0.98 | 0.69 | 0.56 | 0.73 | 0.71 | 1.39 | 1.22 | 0.83 | 1.06 | 2.20 | 1.34 | 2.03 | 1.52 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 216 | 295 | 424 | 433 | 600 | 658 | 655 | 853 | 1,174 | 1,341 | 1,343 | |
| 202 | 266 | 361 | 362 | 486 | 545 | 582 | 713 | 966 | 1,018 | 1,016 | |
| Operating Profit | 14 | 29 | 63 | 71 | 114 | 114 | 73 | 140 | 208 | 324 | 326 |
| OPM % | 6.34% | 9.89% | 14.93% | 16.49% | 18.97% | 17.27% | 11.14% | 16.40% | 17.72% | 24.12% | 24.31% |
| 18 | 7 | 8 | 0 | 31 | 42 | 79 | 62 | 66 | 104 | 119 | |
| Interest | 4 | 8 | 7 | 7 | 5 | 4 | 4 | 1 | 1 | 1 | 1 |
| Depreciation | 15 | 12 | 9 | 12 | 15 | 18 | 17 | 29 | 29 | 34 | 35 |
| Profit before Tax | 12 | 17 | 56 | 53 | 124 | 135 | 132 | 172 | 243 | 392 | 418 |
| Tax % | 3.36% | 25.37% | 22.13% | 28.11% | 20.87% | 22.69% | 22.09% | 22.18% | 22.60% | 23.20% | 23.12% |
| Net Profit | 12 | 12 | 44 | 38 | 98 | 104 | 103 | 134 | 188 | 301 | 322 |
| EPS | 0.28 | 0.30 | 1.07 | 0.93 | 2.40 | 2.54 | 2.48 | 2.95 | 4.15 | 6.64 | — |
| Dividend Payout % | 17.72% | 16.47% | 4.69% | 10.80% | 10.40% | 9.84% | 22.03% | 20.33% | 19.26% | 13.56% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 14%
- 5 Years:
- 17%
- 3 Years:
- 27%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 15%
- 5 Years:
- 25%
- 3 Years:
- 43%
STOCK PRICE CAGR
- 10 Years:
- 22%
- 5 Years:
- 36%
- 3 Years:
- 46%
- 1 Year:
- 87%
RETURN ON EQUITY
- 10 Years:
- 11%
- 5 Years:
- 15%
- 3 Years:
- 15%
- Last Year:
- 20%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 41 | 41 | 41 | 41 | 41 | 45 | 45 | 45 | 45 |
| 378 | 388 | 430 | 465 | 559 | 651 | 1,066 | 1,177 | 1,338 | 1,604 | |
| 84 | 76 | 87 | 13 | 13 | 9 | 5 | 7 | 8 | 9 | |
| Trade Payables | 21 | 34 | 37 | 57 | 64 | 74 | 112 | 160 | 204 | 181 |
| 22 | 21 | 30 | 35 | 84 | 215 | 141 | 159 | 201 | 217 | |
| Total Liabilities | 546 | 560 | 625 | 610 | 761 | 989 | 1,369 | 1,548 | 1,796 | 2,056 |
| 94 | 88 | 103 | 115 | 129 | 136 | 144 | 272 | 383 | 398 | |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| 234 | 236 | 236 | 236 | 236 | 237 | 266 | 293 | 266 | 267 | |
| 29 | 42 | 70 | 75 | 94 | 104 | 131 | 191 | 205 | 189 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 370 | 550 | 623 | |
| Cash & Bank | 3 | 1 | 2 | 3 | 106 | 224 | 440 | 312 | 269 | 447 |
| 185 | 193 | 214 | 181 | 196 | 290 | 384 | 111 | 123 | 131 | |
| Total Assets | 546 | 560 | 625 | 610 | 761 | 989 | 1,369 | 1,548 | 1,796 | 2,056 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 20 | 33 | 118 | 127 | 88 | 83 | 34 | 31 | 211 | |
| Cash from Investing | -8 | -8 | -20 | -24 | 9 | -128 | -195 | -114 | 17 | -140 |
| Cash from Financing | 21 | -10 | 1 | -82 | -14 | 71 | 210 | -26 | -30 | -39 |
| -1 | -2 | 1 | 2 | 102 | -1 | 67 | -106 | 18 | 32 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-07 - Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPF
2026-09-01 - Marksans Pharma Limited has informed the Exchange about Schedule of Investors Meet
2026-08-27 - Marksans Pharma Limited has submitted the Exchange a copy Srutinizers report along with voting result of Annual General Meeting held on August 27, 2026.
2026-08-27 - Marksans Pharma Limited has informed the Exchange regarding Proceedings of 34th Annual General Meeting held on August 27, 2026
2026-08-26 - Intimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ESG score by Crisil ESG Ratings & Analytics Ltd
2026-08-20 - Marksans Pharma Limited has informed the Exchange about Transcript of Investors/Analyst meet Q1 FY 27 Financial Results
2026-08-13 - Marksans Pharma Limited has informed the Exchange about Link of Recording of Conference call Q1 FY 27 Financial Results
2026-08-13 - Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication for Unaudited financial results for the quarter ended June 30, 2026
2026-08-12 - Marksans Pharma Limited has informed the Exchange regarding a press release dated August 12, 2026, titled "Press Release dated 12 August 2026 on the unaudited financial results of the Company for the quarter ended 30 June 2026".
News
Recent coverage and analyst commentary for MARKSANS
Loading news…
AI Stock Analyst
Marksans Pharma Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account